Literature DB >> 9851042

Analysis of the Mycobacterium bovis hsp60 promoter activity in recombinant Mycobacterium avium.

G Batoni1, G Maisetta, W Florio, G Freer, M Campa, S Senesi.   

Abstract

A clinical isolate of Mycobacterium avium was transformed with a new shuttle plasmid containing the Escherichia coli beta-galactosidase reporter gene under the control of the Mycobacterium bovis bacillus Calmette-Guérin (BCG) hsp60 promoter. beta-Galactosidase activity was assayed spectrophotometrically in bacterial homogenates of the recombinant strain (M. avium::lacZ) and used for quantification of the hsp60 promoter strength in different conditions of extra- and intracellular growth. Very low levels of beta-galactosidase were recorded during the exponential phase of in vitro growth, while they increased progressively during the late exponential and stationary phases. A significant increase in enzyme activity was also induced in exponentially growing cells by shifting the incubation temperature from 37 to 45 degrees C, but not from 37 to 42 degrees C nor from 30 to 42 degrees C. No induction of the promoter was observed by adding hydrogen peroxide to the cultures. Finally, beta-galactosidase levels were quantified during growth of M. avium::lacZ in murine macrophages. Soon after phagocytosis and, to a lesser extent at 1, 5 and 7 days after infection, increased levels of bacterial beta-galactosidase were observed indicating an increment in transcriptional activity of hsp60 promoter both at early phases of infection and during the course of intracellular growth.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851042     DOI: 10.1111/j.1574-6968.1998.tb13307.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  7 in total

1.  Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells.

Authors:  Eleanor J Cheadle; Dearbhaile O'Donnell; Peter J Selby; Andrew M Jackson
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

2.  Brucella abortus strain RB51 as a vector for heterologous protein expression and induction of specific Th1 type immune responses.

Authors:  R Vemulapalli; Y He; S M Boyle; N Sriranganathan; G G Schurig
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

3.  Use of a recombinant strain of Mycobacterium avium expressing beta-galactosidase to evaluate the activities of antimycobacterial agents inside macrophages.

Authors:  G Maisetta; G Batoni; M Pardini; A Boschi; D Bottai; S Esin; M Campa; S Senesi
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

4.  Transcriptome Landscape of Mycobacterium smegmatis.

Authors:  Xinfeng Li; Han Mei; Fang Chen; Qing Tang; Zhaoqing Yu; Xiaojian Cao; Binda T Andongma; Shan-Ho Chou; Jin He
Journal:  Front Microbiol       Date:  2017-12-18       Impact factor: 5.640

5.  Construction of E. coli-Mycobacterium shuttle vectors with a variety of expression systems and polypeptide tags for gene expression in mycobacteria.

Authors:  Surya Pratap Seniya; Priya Yadav; Vikas Jain
Journal:  PLoS One       Date:  2020-03-11       Impact factor: 3.240

6.  LysX2 is a Mycobacterium tuberculosis membrane protein with an extracytoplasmic MprF-like domain.

Authors:  Francesca Boldrin; Laura Cioetto Mazzabò; Marie-Antoinette Lanéelle; Laura Rindi; Greta Segafreddo; Anne Lemassu; Gilles Etienne; Marta Conflitti; Mamadou Daffé; Alfredo Garzino Demo; Riccardo Manganelli; Hedia Marrakchi; Roberta Provvedi
Journal:  BMC Microbiol       Date:  2022-04-01       Impact factor: 3.605

7.  The mycobacterial DNA-binding protein 1 (MDP1) from Mycobacterium bovis BCG influences various growth characteristics.

Authors:  Astrid Lewin; Daniela Baus; Elisabeth Kamal; Fabienne Bon; Ralph Kunisch; Sven Maurischat; Michaela Adonopoulou; Katharina Eich
Journal:  BMC Microbiol       Date:  2008-06-10       Impact factor: 3.605

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.